Cite
HARVARD Citation
Kantak, S. et al. (n.d.). 630 PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models. Journal for immunotherapy of cancer. p. A378. [Online].